Skip to content

Assessment of the Results of Medivim Filler Injections to Correction Nasolabial Folds

Evaluation of efficacy and safety of "MediVim" HA dermal fillers in correction of moderate-to-severe Nasolabial folds

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20220723055530N3
Enrollment
33
Registered
2024-01-06
Start date
2024-01-07
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin aging.

Interventions

Intervention group: Injection of Medivim Intradermal filler in the nasolabial folds, the products are in the 1 ml pre-filled sterilized syringe containing:Medivim:Hyaluronic Acid gel 24 mg

Sponsors

Nik Sina Eksir
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 65 Years

Inclusion criteria

Inclusion criteria: 30 -65 Years old men and women with moderate to severe nasolabial folds Signing the informed consent form

Exclusion criteria

Exclusion criteria: History of a cosmetic procedure in the lower 2/3 of the face during the last three months Previous allergy to Hyaluronic Acid or Lidocaine Presence of inflammation, active infection, unhealed old wound, and skin lesions in the NLF region People prone to hypertrophic scar formation History of autoimmune or immune deficiency diseases Pregnancy or breastfeeding

Design outcomes

Primary

MeasureTime frame
Severity of nasolabial folds. Timepoint: Before intervention, immediately after that, 2 weeks, and 3 months later. Method of measurement: Five-point photonumeric Allergan scale.

Secondary

MeasureTime frame
Area, depth, and volume of nasolabial folds. Timepoint: Before the intervention, immediately after that, 2 weeks, and 3 months later. Method of measurement: Visioface camera.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Nasimi

Tehran University of Medical Sciences

nsm.maryam@gmail.com+98 21 5563 0705

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026